NEW YORK, July 23, 2024 /PRNewswire/ -- The
global amyotrophic lateral sclerosis treatment market size is
estimated to grow by USD 663.7
million from 2024-2028, according to Technavio. The
market is estimated to grow at a CAGR of 12.79% during the forecast
period. Increase in incidence and prevalence of amyotrophic
lateral sclerosis is driving market growth, with a trend
towards increase in aging population. However, high cost
of treatment poses a challenge. Key market players include AB
Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive
Therapeutics Inc., Biogen Inc.,Brainstorm Cell Therapeutics
Inc.,CORESTEM Inc.,Cytokinetics Inc.,Denali Therapeutics Inc., Dr
Reddys Laboratories Ltd., Eledon Pharmaceuticals Inc.,Ionis
Pharmaceuticals Inc.,Italfarmaco Holding SPA, Medindia Health,
Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd.,
Revalesio Corp.,Sanofi, Sun Pharmaceutical Industries Ltd., and
Treeway BV.
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Type (Intravenous and
Oral), Distribution Channel (Hospital pharmacies, Retail
pharmacies, and Online pharmacies), and Geography (North America,
Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
AB Science SA, Alkem
Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc., Biogen
Inc., Brainstorm Cell Therapeutics Inc., CORESTEM Inc.,
Cytokinetics Inc., Denali Therapeutics Inc., Dr Reddys Laboratories
Ltd., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc.,
Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group
Corp., Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi, Sun
Pharmaceutical Industries Ltd., and Treeway BV
|
Key Market Trends Fueling Growth
The global aging population is on the rise, with the proportion
of individuals over 60 years expected to nearly double from 12% to
22% between 2015 and 2050, according to the World Health
Organization (WHO). This demographic shift increases the risk of
developing neurological disorders, including Amyotrophic Lateral
Sclerosis (ALS), which is more common in the elderly. In
Sub-Saharan Africa, degenerative diseases such as Alzheimer's
disease and Parkinson's disease are the most common neurological
disorders reported. Consequently, the increasing elderly population
will drive the growth of the global ALS treatment market during the
forecast period.
The Amyotrophic Lateral Sclerosis (ALS) treatment market is
witnessing significant growth due to increasing awareness about
this neurodegenerative disorder, affecting the central nervous
system and leading to the degeneration of voluntary muscles. The
market is segmented into hospital pharmacies, retail pharmacies,
and online providers. The geriatric population, with a higher
incidence rate, is a key target. Ursodoxicoltaurine is a popular
drug therapy, but infection rates remain a concern. The market is
dominated by sporadic and familial types, with men and women
equally affected. Stationary lifestyle and less awareness
contribute to insubstantial treatment options. Immunosuppressants
and reimbursement scenarios are critical factors in the healthcare
expenditure. NeuroSense Therapeutics' new drug, targeting gene
mutation and Glutamate, has secured seed funding, offering hope for
ALS patients. Medical technology advances include ALS drugs,
physical therapy, speech therapy, and stem cell therapies. The
market faces challenges due to expensive treatment and healthcare
infrastructure limitations.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
• Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder
affecting nerve cells responsible for voluntary muscle movement.
Individuals with ALS face challenges in swallowing and chewing
food, increasing the risk of choking. The FDA has approved two
medications, Radicava and Rilutek, for ALS treatment. Radicava
costs around USD1,000 per infusion,
with an annual treatment cost of approximately USD146,000. Rilutek costs up to USD12,000 per year. Physical therapies to improve
flexibility and strength cost between USD50 and USD350
per session. Tracheostomy, a surgical procedure to create a
breathing hole, can cost up to USD150,000, while invasive ventilation ranges
from USD150,000 to USD330,000 per year. High treatment costs may
hinder the growth of the global ALS treatment market.
• The Amyotrophic Lateral Sclerosis (ALS) treatment market
faces challenges in various sectors. Hospital and retail pharmacies
struggle with ensuring consistent supply of ALS drugs due to high
demand and limited availability. Ursodoxicoltaurine, a potential
ALS treatment, requires more awareness among healthcare providers
and the geriatric population due to its insubstantial use. The
incidence rate of ALS, a neurodegenerative disorder affecting the
central nervous system and causing voluntary muscle weakness, is
increasing, putting pressure on expensive treatment options. The
sporadic and familial types of ALS affect both men and women, and
the stationary lifestyle of patients increases infection rates.
Immunosuppressants used in ALS treatment have a complex
reimbursement scenario, adding to healthcare expenditure.
NeuroSense Therapeutics is working on a new drug, with seed funding
in genetics and biomarkers, to address the lack of effective
treatments for ALS. ALS drugs require specialized healthcare
infrastructure, and physical therapy, speech therapy, and stem cell
therapies are essential components of treatment. The less awareness
about ALS and its symptoms hampers early diagnosis and effective
treatment. The expensive treatment and insubstantial treatment
options call for innovative medical technology solutions to improve
patient care.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This amyotrophic lateral sclerosis treatment market report
extensively covers market segmentation by
- Type
- Distribution Channel
- 2.1 Hospital pharmacies
- 2.2 Retail pharmacies
- 2.3 Online pharmacies
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Intravenous- The Amyotrophic Lateral Sclerosis
(ALS) treatment market is experiencing growth due to the rising
prevalence of this neurological disorder. According to the Centers
for Disease Control and Prevention (CDC), approximately 5.2 cases
per 100,000 people in the US have ALS, amounting to 16,583
identified cases in 2021. Annually, around 30,000 new cases are
diagnosed in the US. With most cases being sporadic and 5%-10%
being familial, a significant portion involves a mutation of the
SOD1 gene. Despite the availability of treatments, such as Riluzole
and Edaravone, the market growth is expected to decelerate due to
modest improvements and the inconvenience of infusion therapy for
immobile patients on ventilation. Consequently, the intravenous
segment of the global ALS treatment market is anticipated to expand
during the forecast period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The global Concierge Medicine market is witnessing robust
growth, driven by increasing demand for personalized care and
convenience. In parallel, the Multiple Sclerosis Drugs market is
expanding due to advancements in drug development and a rise in MS
cases. Meanwhile, the Oligonucleotide Therapeutics market is
experiencing significant expansion, fueled by innovations in
genetic therapies and growing investments in biotechnology. These
markets are set to see continued growth as they address critical
health needs and leverage cutting-edge technologies to improve
patient outcomes.
Research Analysis
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative
disorder that affects nerve cells in the central nervous system,
leading to the degeneration and death of motor neurons. This
condition results in the loss of the ability to control voluntary
muscles, eventually leading to respiratory failure. The disease can
be inherited genetically or occur sporadically, with a higher
incidence rate in men than women. The cause of ALS is not fully
understood, but research suggests a possible link to gene mutations
and environmental factors. ALS affects the population of all ages,
but the geriatric population is more susceptible. The disease can
lead to infection rates due to weakened immune systems and
difficulty in swallowing and breathing. Hospital pharmacies, retail
pharmacies, and online providers play a crucial role in providing
drug therapies to manage the symptoms of ALS. Ursodicotaurine is
one of the drug therapies used to treat ALS. The high cost of
treatment and the stationary lifestyle required by patients make it
a challenging condition to manage. Awareness about ALS is
increasing, leading to more research and development of new
treatments. However, the current treatments are expensive, and
access to them can be a challenge for many patients. The disease
affects both men and women, and its cause is still not fully
understood, making it a complex and challenging condition to
treat.
Market Research Overview
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative
disorder that affects nerve cells in the central nervous system,
leading to the degeneration and death of motor neurons. This
condition results in the loss of ability to control voluntary
muscles, leading to respiratory failure and eventual death. ALS can
be inherited genetically or occur sporadically, with men and women
affected equally. The disease often affects the geriatric
population and those with a stationary lifestyle. The incidence
rate of ALS is low, with less awareness and insubstantial treatment
options contributing to high healthcare expenditure. Medical
technology offers various treatments, including medication such as
Ursodoxicoltaurine, physical therapy, speech therapy, and stem cell
therapies. Hospital pharmacies, retail pharmacies, and online
providers are key distribution channels for ALS medications. The
reimbursement scenario for ALS drugs is complex, with healthcare
infrastructure playing a crucial role in ensuring access to
treatment. Neurodegenerative disorders like ALS are characterized
by the death of nerve cells, leading to muscle weakness and
wasting. The disease progression is rapid, and there is currently
no cure. Factors such as gene mutation, glutamate toxicity, and
infection rates contribute to the development of ALS. Drug
therapies, immunosuppressants, and biomarkers are being explored to
improve the understanding and treatment of this debilitating
condition. Companies like NeuroSense Therapeutics are focusing on
developing new drugs and technologies to address the unmet medical
need in ALS.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyotrophic-lateral-sclerosis-treatment-market-size-is-set-to-grow-by-usd-663-7-million-from-2024-2028--increase-in-incidence-and-prevalence-of-amyotrophic-lateral-sclerosis-to-boost-the-market-growth-technavio-302202681.html
SOURCE Technavio